FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis

A Prospective, Validation Study of FibroSURE™ and FibroScan® as Screening, Detection, and Monitoring Alternatives to Liver Biopsy for Methotrexate-induced Hepatic Fibrosis and Cirrhosis in Patients With Psoriasis

The purpose of this study is to validate FibroScan and FibroSURE™ as equal or superior alternatives to liver biopsy for the monitoring and detection of methotrexate-induced hepatic fibrosis and cirrhosis in patients with moderate-to-severe psoriasis.

The goals of this study are to validate FibroScan and FibroSURE™ as equal or superior alternatives to liver biopsy. The goal is to evaluate the monitoring and detection of methotrexate-induced hepatic fibrosis and cirrhosis in patients with moderate-to-severe psoriasis.

Inclusion Criteria:

• Male or female greater than or equal to 18 years of age
• Must have a diagnosis of moderate-to-severe psoriasis
• Newly starting methotrexate

Exclusion Criteria:

• Allergy to methotrexate
• History of chronic alcohol abuse
• Diagnosis of liver disease